Brookline Capital Management Forecasts MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for shares of Marker Therapeutics in a research note issued to investors on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($0.66) for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.80) EPS and FY2025 earnings at ($4.36) EPS.

MRKR has been the topic of a number of other research reports. Canaccord Genuity Group started coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target on the stock. WBB Securities reiterated a “strong-buy” rating and issued a $12.50 target price on shares of Marker Therapeutics in a research note on Tuesday.

Marker Therapeutics Price Performance

Marker Therapeutics stock opened at $1.20 on Thursday. Marker Therapeutics has a 12 month low of $1.10 and a 12 month high of $5.99. The business’s fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $2.70.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%. The company had revenue of $1.22 million during the quarter, compared to the consensus estimate of $5.25 million.

Institutional Investors Weigh In On Marker Therapeutics

Institutional investors have recently modified their holdings of the business. Aisling Capital Management LP raised its position in Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after buying an additional 11,084 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Marker Therapeutics during the fourth quarter valued at approximately $50,000. Invst LLC bought a new position in Marker Therapeutics during the third quarter valued at approximately $56,000. Northern Trust Corp boosted its holdings in Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares during the last quarter. Finally, LPL Financial LLC purchased a new stake in Marker Therapeutics in the fourth quarter worth approximately $248,000. 22.39% of the stock is owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.